Lead Pharma News Today

The Drugs Control Administration (DCA), Telangana, has executed 18 successful operations against illicit pharmacies s...

Therapeutics developer Lead Pharmaceutical (Oss, Netherlands) and French medicinal chemistry and custom synthesis company Oxeltis, have been awarded an €800K ($842K) grant from EUREKA Eurostars for a three year project aimed at developing a first-in-class small molecule therapy for diffuse large B-cell lymphoma (DLBCL). Click to read more...

Dutch firm Lead Pharma and French company Oxeltis have been awarded an €800K grant from the 37-nation EUREKA intergovernmental network’s Euro...

Grant will fund three-year EPIGENEXT joint project aimed at developing first-in-class therapy for diffuse large B-cell lymphoma  Oss, the Netherlands and Montpellier, France, June 8, 2022 – Lead Pharma, a privately held pharmaceutical company designing and developing innovative therapies for the treatment of immune-...

In Silico Drug Discovery Market Share, Size, Industry Analysis, Demand, Growth and Research Report 2020-2028 emergenMay 23, 2021 The global In Silico Drug Discovery Market is forecasted to be worth USD 6.34 Billion by 2027, according to a current analysis by Emergen Research. In November 2020, Lead Pharma announced its collaboration and license agreement with Roche for the development of oral small molecules for the treatment of a broad range of immune-mediated diseases. Lead Pharma is using in...

Published: Dec 16, 2020 By Joseph Constance A healthy immune system defends the body against disease and other conditions. However, if the immune system malfunctions, it can attack healthy cells, tissues and organs. Autoimmune disease impacts different parts of the body, weakening functionality. It may be life-threatening. Researchers are aware of more than 80 diseases that occur when the immune system attacks the body’s own organs, tissues and cells. The more common autoimmune diseas...